Physician profile
Tariq Muhammad
NPI 1073561122
$1,771.46
in general payments reported to CMS, 2019-2025
17 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $102 · 2021: $237 · 2022: $302 · 2023: $293 · 2024: $270 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674 · Education: $30.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.52 |
| Education | $30.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $309.50 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $228.27 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $195.99 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $193.91 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $171.00 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $170.23 | 2019-2023 | Korsuva, Veltassa |
| Amgen INC. | $82.65 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $72.09 | 2023 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $59.69 | 2023-2025 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $56.35 | 2022-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $54.70 | 2020 | |
| Lilly USA, LLC | $49.60 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $39.67 | 2019 | |
| Glaxosmithkline, LLC. | $29.51 | 2022-2023 | Benlysta |
| Travere Therapeutics, INC. | $22.89 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $19.10 | 2023 | Ibsrela |
| Genzyme Corporation | $16.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tariq Muhammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.